Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MTVA
MTVA logo

MTVA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy MetaVia Inc (MTVA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.040
1 Day change
-4.59%
52 Week Range
19.030
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

MetaVia Inc (MTVA) is not a strong buy for a long-term beginner investor at this time. The lack of positive financial performance, absence of significant trading trends, and no strong technical or proprietary trading signals suggest that the stock does not present a compelling investment opportunity currently. Additionally, the company's financials show a significant decline in net income and EPS, which is a negative indicator for long-term growth potential.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 58.514, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 1.455, with resistance at 1.631 and support at 1.28. Overall, the technical indicators do not suggest a strong buy signal.

Positive Catalysts

  • NULL identified. There is no recent news or significant trading activity from insiders or hedge funds.

Neutral/Negative Catalysts

  • The company's financial performance in Q4 2025 shows a significant decline in net income (-62.69% YoY) and EPS (-84.86% YoY). There is no recent news or events to drive positive sentiment.

Financial Performance

In Q4 2025, revenue remained stagnant at 0, while net income dropped to -1,930,000 (-62.69% YoY), and EPS fell to -0.84 (-84.86% YoY). Gross margin also remained at 0, showing no growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on recent analyst ratings or price target changes is available.

Wall Street analysts forecast MTVA stock price to rise
2 Analyst Rating
Wall Street analysts forecast MTVA stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.040
sliders
Low
40
Averages
47.5
High
55
Current: 1.040
sliders
Low
40
Averages
47.5
High
55
H.C. Wainwright
Andrew Fein
initiated
$12
AI Analysis
2025-09-04
Reason
H.C. Wainwright
Andrew Fein
Price Target
$12
AI Analysis
2025-09-04
initiated
Reason
H.C. Wainwright analyst Andrew Fein assumed coverage of MetaVia with a Buy rating and $12 price target. The firm says Metavia offers a \"compelling opportunity\" in the metabolic disease space based on its two \"differentiated\" pipeline programs.
Maxim
Jason McCarthy
Buy
downgrade
$6 -> $3
2025-05-19
Reason
Maxim
Jason McCarthy
Price Target
$6 -> $3
2025-05-19
downgrade
Buy
Reason
Maxim analyst Jason McCarthy lowered the firm's price target on MetaVia to $3 from $6 and keeps a Buy rating on the shares. The firm cites the company's Q1 results, cash update, and its recent $10M financing in adjusting its model, though it remains positive on MetaVia's obesity (DA-1726) and MASH (DA-1241) treatment opportunities, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MTVA
Unlock Now

People Also Watch